Business Description
Achilles Therapeutics PLC
ISIN : US00449L1026
Share Class Description:
STU:698: ADRDescription
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.31 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -29.6 | |||||
| 3-Year EPS without NRI Growth Rate | -28.7 | |||||
| 3-Year FCF Growth Rate | -10.7 | |||||
| 3-Year Book Growth Rate | -9.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -16.62 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.56 | |||||
| 9-Day RSI | 69.35 | |||||
| 14-Day RSI | 67.09 | |||||
| 6-1 Month Momentum % | 3.57 | |||||
| 12-1 Month Momentum % | 12.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.24 | |||||
| Quick Ratio | 8.24 | |||||
| Cash Ratio | 6.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.4 | |||||
| Shareholder Yield % | 7.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -44.7 | |||||
| ROA % | -39.41 | |||||
| ROIC % | -249.56 | |||||
| 3-Year ROIIC % | 307.72 | |||||
| ROC (Joel Greenblatt) % | -345.36 | |||||
| ROCE % | -48.47 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.37 | |||||
| EV-to-EBIT | 0.65 | |||||
| EV-to-EBITDA | 0.68 | |||||
| EV-to-FCF | 2.54 | |||||
| Price-to-Net-Current-Asset-Value | 0.42 | |||||
| Price-to-Net-Cash | 0.54 | |||||
| Earnings Yield (Greenblatt) % | 153.16 | |||||
| FCF Yield % | -41.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Achilles Therapeutics PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.473 | ||
| Beta | 0.35 | ||
| Volatility % | 74.87 | ||
| 14-Day RSI | 67.09 | ||
| 14-Day ATR (€) | 0.016888 | ||
| 20-Day SMA (€) | 0.91825 | ||
| 12-1 Month Momentum % | 12.99 | ||
| 52-Week Range (€) | 0.615 - 1.44 | ||
| Shares Outstanding (Mil) | 41.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Achilles Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Achilles Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Achilles Therapeutics PLC Frequently Asked Questions
What is Achilles Therapeutics PLC(STU:698)'s stock price today?
The current price of STU:698 is €0.96. The 52 week high of STU:698 is €1.44 and 52 week low is €0.62.
When is next earnings date of Achilles Therapeutics PLC(STU:698)?
The next earnings date of Achilles Therapeutics PLC(STU:698) is 2024-11-14 Est..
Does Achilles Therapeutics PLC(STU:698) pay dividends? If so, how much?
Achilles Therapeutics PLC(STU:698) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers